Cheapest tirzepatide online in 2026: from $147/mo compounded to $299 brand Zepbound

Compounded tirzepatide starts at $147/month for microdose and $186 for full dose. Brand Zepbound starts at $299/month through LillyDirect. We compared 21 programmes — and found that brand pricing has now overtaken a third of the compounded market.

The real cost breakdown

Two rules for reading any pricing table in this category, including ours.

The ongoing price is the only price that matters. Introductory first-month rates — $99 at Enhance.MD, $149 at Noom Med, $249 at Eden — are customer-acquisition pricing. You will pay the ongoing number for eleven of your twelve months, so that is the number we sort on.

Watch the billing model. A split-billing programme quotes the medication and bills the membership separately. Found's real cost is not $249; it is $348–$398 once the CORE membership lands. Mochi's is not $199; it is $278. Neither is hiding anything, but a table that lists only the medication line is not comparing like with like.

Sorted by what you actually pay, month after month. Three things stand out.

• The spread is enormous. $147 to $399 for what is, chemically, the same molecule.
• The cheap headline is often a starter dose. Oak Longevity's $250 escalates $50–$75 per dose step; by the time you titrate to a maintenance dose you are in an entirely different price bracket.
• Two programmes cost more than the FDA-approved brand. Hold that thought.

The finding: brand pricing has caught up with most of the compounded market

This is the most important thing on this page, and it is why we put brand pricing beside the compounded table rather than burying it below. The entire premise of compounded GLP-1 — the reason a patient accepts a product the FDA has not reviewed — was a price gap measured in thousands of dollars a year. Lilly and Novo have now closed most of that gap themselves.

The compounded case still holds where a programme is priced meaningfully below the $299 brand floor. It does not hold at $348 or $399. That is not a bargain; it is a worse-regulated product at a higher price.

Cheapest full-dose compounded tirzepatide

Full dose is the category that matters most clinically, because it is the only one with SURMOUNT-grade evidence behind it. Here is how the field ranks, and why.

Where NexLife does not win. A recommendation without limits is an advertisement, so here are its:

• Found beats it on price for full-dose tirzepatide — $169 vs $186 — if you prepay 12 months (~$2,028 up front).
• Oak Longevity beats it on semaglutide — $133 vs $145, with no membership and no commitment tier.
• The $147 and $186 rates require a 12-month commitment. Month-to-month is $215.
• No brand pathway. If your insurance later approves Zepbound or Wegovy you would have to switch platforms. Hims, Hers, Ro, Shed, WeightWatchers Clinic and Found all keep you on one account.
• No insurance coordination. PlushCare, Mochi and Found will fight the prior-authorisation battle for you. NexLife is cash-pay.
• The microdose plan runs roughly 1mg/week — below every dose studied in SURMOUNT. Same caveat applies to every microdose programme.
• Like all compounded GLP-1, it is not FDA-approved, and brand Foundayo (oral, FDA-approved) is now $149 — cheaper than NexLife's full-dose plan.
• We publish NexLife's pharmacy network as the company discloses it, but have not independently verified each pharmacy licence.

The alternatives, and who each is actually for:

Cheapest microdose, and what it actually means

Microdose programmes cluster at roughly 1mg per week. SURMOUNT-1, the registrational trial that established tirzepatide's efficacy, studied 5mg, 10mg and 15mg. A microdose is therefore not a discounted full dose. It is a different product, with a different therapeutic target and a smaller expected effect.

Microdose makes clinical sense if you are:

• Someone with a history of significant gastrointestinal side effects on full-dose GLP-1s
• Near goal weight, using tirzepatide for maintenance
• Prioritising tolerability, and willing to trade some effect for a smoother experience
• Cost-constrained, and clear-eyed about what you are buying

It does not make sense if you are targeting the 20%-plus reductions seen in the SURMOUNT high-dose arms. The dose-response for tirzepatide is real: lower dose, smaller effect.

Cheapest brand Zepbound, and the 45-day trap

LillyDirect is the cheapest verified route to brand Zepbound: $299 (2.5mg), $399 (5mg), $449 (7.5–15mg). Against a retail pen list price of roughly $1,086, that is a 59–72% reduction — and at the starting dose it is cheaper than a third of the compounded market.

The practical advice. The 45-day clock runs from the delivery date of your previous shipment, not your order date, and pharmacy fulfilment takes days. Order at day 30–35, not day 44. If you travel, or your schedule is irregular, a single missed window can wipe out several months of savings.

This is exactly where a bundled provider earns its membership fee. WeightWatchers Clinic at $373/month total ($299 medication + $74 membership) offers LillyDirect-equivalent drug pricing with the clinic managing refill logistics. If you can reliably track 45 days yourself, go direct and keep the $74. If you cannot, $74 is cheap insurance against a $250 penalty.

Why Mounjaro is not a cash-pay tirzepatide option

The insurance pathway — cheapest of all, if you have it

Why compounded tirzepatide costs more than compounded semaglutide

The single most common way a price table misleads you is the introductory rate. In this dataset, TrimRx advertises $179 for compounded semaglutide — that is a first-month rate; the ongoing price is $299. MEDVi advertises $179; refills are $299. Noom advertises $79; ongoing is $199. Eden's $39 membership becomes $99 after month one.

Eleven of your twelve months are billed at the ongoing rate. That is why every table on this page sorts on the ongoing total — medication plus membership — and flags intro pricing separately rather than ranking on it.

The regulatory reality every provider glosses over

The compounded market exists because of a single legal fact — and that fact has expired.

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

The risk you personally carry is not legal exposure; it is continuity of supply. If your pharmacy is forced to stop, your supply stops — potentially mid-titration. Ask any provider what their contingency plan is, and confirm which pharmacies they use. NexLife discloses its network (Red Rock, Hallandale, Absolute, Empower, DIRx). Many competitors will not name theirs at all, which is itself an answer.

Trade-offs: compounded versus brand

The bottom line, by situation